Developmental and Epileptic Encephalopathies (DEE) consists of several types of severe brain disorders in which the epileptic electrical discharges may add to progressive psychomotor dysfunction. They are a group of nosologies that are related to an early age and manifest with electroencephalography (EEG) paroxysmal activity that is often aggressive, seizures that are commonly multi-form and intractable, cognitive, behavioral and neurological deficits that may be relentless and sometimes lead to early death. Cognitive deficits and behavioral disturbances are presumed to be the main and sometimes the first and unique manifestation of electrographic epileptic discharges in epileptic encephalopathy. There are various sub syndromes in Epileptic encephalopathies namely West syndrome, Dravet syndrome, Ohtahara syndrome, Lennox-gastaut, Landau-Kleffner syndrome, Epilepsy with Continuous Spike-and -Waves during Slow-Wave Sleep, Myoclonic Status in Non-Progressive Encephalopathies, Atypical Benign Partial Epilepsy of Childhood, Hypothalamic (Gelastic) Epilepsy.
This report contains market size and forecasts of Developmental and Epileptic Encephalopathies (DEE) in Global, including the following market information:
Global Developmental and Epileptic Encephalopathies (DEE) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Developmental and Epileptic Encephalopathies (DEE) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Atypical Benign Partial Epilepsy of Childhood Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Developmental and Epileptic Encephalopathies (DEE) include Biocodex, Bio-Pharm Solutions, Eisai Pharmaceuticals, GlaxoSmithKline, Greenwich Biosciences, Janssen Pharmaceuticals, Lundbeck, Mylan Pharmaceuticals and PTC Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Developmental and Epileptic Encephalopathies (DEE) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Developmental and Epileptic Encephalopathies (DEE) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Developmental and Epileptic Encephalopathies (DEE) Market Segment Percentages, by Type, 2021 (%)
Atypical Benign Partial Epilepsy of Childhood
Dravet Syndrome
Epilepsy with Continuous Spike-and -Waves during Slow-Wave Sleep
Hypothalamic Epilepsy
Landau-Kleffner Syndrome (LKS)
Lennox-Gastaut Syndrome
Myoclonic Status in Non-Progressive Encephalopathies
West Syndrome
Global Developmental and Epileptic Encephalopathies (DEE) Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Developmental and Epileptic Encephalopathies (DEE) Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global Developmental and Epileptic Encephalopathies (DEE) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Developmental and Epileptic Encephalopathies (DEE) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Developmental and Epileptic Encephalopathies (DEE) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Developmental and Epileptic Encephalopathies (DEE) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biocodex
Bio-Pharm Solutions
Eisai Pharmaceuticals
GlaxoSmithKline
Greenwich Biosciences
Janssen Pharmaceuticals
Lundbeck
Mylan Pharmaceuticals
PTC Therapeutics
Roche
Takeda Pharmaceutical
Zogenix
Zynerba Pharma
Ovid Therapeutics